XBiotech Inc. Issues Correction Clarifying Director Craig Rademaker's Role with Canadian Private Equity Firms
XBiotech Inc. has clarified that director Craig Rademaker serves as a consultant to several Canadian private equity firms, focusing on capital markets activities. This correction follows their June 24, 2025 Form 8-K filing. The information is part of a news brief generated by Public Technologies, which emphasizes that the content is for informational purposes only and not financial or legal advice.
XBiotech Inc. has issued a clarification regarding its earlier June 24, 2025 Form 8-K filing, stating that director Craig Rademaker is a consultant to a number of Canadian private equity firms, with responsibilities principally including capital markets activities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XBiotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-006441), on October 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
